MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Watch Listen Read
Login Nexus Watchlists Settings
  • MARKETSnap
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Investment Compounding Calculator
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Theme Style
Switch to Dark Mode
UTHR stock logo

UTHR

United Therapeutics Corporation

$312.23
1.57
 (0.51%)
Exchange:   NASDAQ
Market Cap:   14.121B
Shares Outstanding:   16.644M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Martine A. Rothblatt
Full Time Employees:  1305
Address: 
1040 Spring Street
Silver Spring
MD
20910
US
Website:  https://www.unither.com
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

EPS

🔒 You are currently logged out

Login
View full analyst estimates

Earnings Call

🔒 You are currently logged out

Login
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Balance Sheet

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Cash Flow Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Analyst Estimates

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Current Key Metrics

🔒 You are currently logged out

Login

Forward P/E Ratios

🔒 You are currently logged out

Login

SWOT Analysis

🔒 You are currently logged out

Login

At what price to buy it? –
Intrinsic Value Calculator

🔒 Premium Feature

Log in to access the UTHR Intrinsic Value Calculator

🔑 Log In
📝 Sign Up Free

Get comprehensive stock analysis with premium features

🔒 You are currently logged out

Login
MS_Stock_Embed class not found. Please check plugin configuration.

Relevant news